Abstract Details

Title Pediatric MOGAD: Clinical Experience in a Tertiary Care Setting

Topic Autoimmune Neurology

Presentation(s) C13 - Neuromyelitis Optica and MOG-antibody Associated Disease Diagnosis and Treatment (11:11 AM-11:18 AM)
P3 - Poster Session 3 (12:00 PM-1:00 PM)

Poster/Presentation
Number 052

Objective To describe a large single-center cohort of children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) since the clinical availability of the MOG antibody cell-based assay.

Background MOGAD is an inflammatory disease of the central nervous system with various phenotypes, with a predilection towards pediatric patients.

Design/Methods Retrospective chart review was performed on patients that underwent MOG antibody testing from 2018 to present. Clinical and demographic data were collected.

Results 113 patients with a diagnosis of MOGAD were identified. Median age at presentation was 8.89 years (2-18 years). Fifty-eight patients (53%) were female. Majority of patients identified as white Hispanic (54%), white non-Hispanic (26%), or black (9%) with the remainder being Asian/Pacific Islander. Predominant clinical phenotypes included acute disseminated encephalomyelitis (44%), optic neuritis (36%), encephalitis (12%), and other demyelinating disease (8%). In follow up to date, 39% of patients have experienced clinical relapse; 23 patients having had an isolated relapse, while 10 had numerous clinical relapses. Average time to relapse is 15.8 months, with 70% of relapses occurring within 6 months of initial presentation. Currently, the longest duration from initial presentation to clinical relapse is 6.8 years. An additional 5 patients were found to have positive MOG cell-based assay but ultimately received alternative diagnoses.

Conclusions Here we present a large single-center cohort of pediatric MOGAD. This adds to the current existing literature of pediatric MOGAD and highlights the need for further longitudinal follow-up to better characterize outcomes of MOGAD, including relapse risks which may help further guide decision making in treatment. Additionally, given phenotypic variability, there is need for future multi-center collaboration in the development of registries or natural history studies for large scale data collection.

Authors/Disclosures
Karla Salazar, MD (Baylor College of Medicine) PRESENTER	Dr. Salazar has nothing to disclose.
Jonathan Yarimi, MD (Memorial Healthcare)	Dr. Yarimi has nothing to disclose.
Kristen Fisher, DO (Baylor College of Medicine)	Dr. Fisher has nothing to disclose.

��ɫ��

��ɫ��